Profiling the targets of these compounds distinguishes certain KMT2Ar leukemias in which DOT1L is enriched at KMT2A fusion oncoprotein target sites, thus providing a strategy for selecting patients for whom treatment with DOT1L-targeting compounds is suitable. The gene discussed is DOT1L; the disease is leukemia.